Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Select Advanced Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT05306340
What this trial is testing

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Who this might be right for
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Genentech, Inc. 373
Early research (Phase 1)Study completedNCT03652077
What this trial is testing

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Who this might be right for
Cervical CancerGastric CancerStomach Cancer+18 more
Incyte Corporation 40
Early research (Phase 1)Active Not RecruitingNCT03983954
What this trial is testing

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

Who this might be right for
ER+ Breast CancerOvarian CancerCervical Squamous Cell Carcinoma+17 more
NeoTX Therapeutics Ltd. 120
Early research (Phase 1)Study completedNCT02143635
What this trial is testing

Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt

Who this might be right for
Advanced Solid and Hematological TP53wt Tumors
Novartis Pharmaceuticals 208
Testing effectiveness (Phase 2)Study completedNCT02454972
What this trial is testing

Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
PharmaMar 345
Large-scale testing (Phase 3)Looking for participantsNCT07060807
What this trial is testing

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Who this might be right for
Breast Neoplasms
Merck Sharp & Dohme LLC 1,000
Testing effectiveness (Phase 2)Looking for participantsNCT07158918
What this trial is testing

ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

Who this might be right for
Solid Tumors
ABL Bio, Inc. 65
Large-scale testing (Phase 3)Study completedNCT01945775
What this trial is testing

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

Who this might be right for
Breast NeoplasmsBRCA 1 Gene MutationBRCA 2 Gene Mutation
Pfizer 431
Testing effectiveness (Phase 2)Looking for participantsNCT03874026
What this trial is testing

Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients

Who this might be right for
Colorectal CancerADCC
National Cancer Institute, Naples 34
Testing effectiveness (Phase 2)Looking for participantsNCT07523529
What this trial is testing

Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors

Who this might be right for
Advanced UnresectableMetastatic
Beijing Biotech 72
Large-scale testing (Phase 3)Looking for participantsNCT07419295
What this trial is testing

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

Who this might be right for
Bladder Cancer
Merck Sharp & Dohme LLC 590
Testing effectiveness (Phase 2)Temporarily pausedNCT01226056
What this trial is testing

Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets

Who this might be right for
Advanced Solid Tumors
Southern Europe New Drug Organization 45
Testing effectiveness (Phase 2)Study completedNCT00038857
What this trial is testing

Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases

Who this might be right for
LeukemiaLymphoma
M.D. Anderson Cancer Center 29
Early research (Phase 1)Study completedNCT01316822
What this trial is testing

ARRY-382 in Patients With Selected Advanced or Metastatic Cancers

Who this might be right for
Metastatic Cancer
Array Biopharma, now a wholly owned subsidiary of Pfizer 26
Testing effectiveness (Phase 2)WithdrawnNCT06099418
What this trial is testing

Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

Who this might be right for
HPV-Related Cervical CarcinomaHPV-Related MalignancyCervical Cancer
Nykode Therapeutics ASA
Testing effectiveness (Phase 2)Study completedNCT03473925
What this trial is testing

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

Who this might be right for
Solid TumorsNon-small Cell Lung CancerCastration Resistant Prostate Cancer+1 more
Merck Sharp & Dohme LLC 107
Large-scale testing (Phase 3)Looking for participantsNCT07533123
What this trial is testing

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

Who this might be right for
Triple Negative Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 364
Testing effectiveness (Phase 2)Study completedNCT02419417
What this trial is testing

Study of BMS-986158 in Subjects With Select Advanced Cancers

Who this might be right for
Advanced Tumors
Bristol-Myers Squibb 83
Early research (Phase 1)Study completedNCT01831089
What this trial is testing

Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors

Who this might be right for
Breast CancerOvarian CancerGynecological Cancer+4 more
PharmaMar 69
Large-scale testing (Phase 3)UnknownNCT05954442
What this trial is testing

Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype

Who this might be right for
Triple Negative Breast CancerMetastatic Breast CancerMutation
Fudan University 203
Next Page